Trial Details
COMPLETEDBasic Information
| Clinical ID | c1515 |
|---|---|
| Identifier | NCT03398148 |
| Trial Title | A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Ulcerative Colitis (UC) |
| Interventions | DRUG: risankizumab IV|DRUG: placebo for risankizumab|DRUG: risankizumab SC |
Participant Information
| Sponsor | AbbVie |
|---|---|
| City | Coronado |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | CHILD, ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE2|PHASE3 |
Time Information
| Start Date | 2018-03-07 |
|---|---|
| Primary Completion Date | 2022-11-09 |
| Completion Date | 2023-05-11 |